Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) CEO Robert I. Blum sold 5,000 shares of the firm's stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $51.63, for a total transaction of $258,150.00. Following the completion of the sale, the chief executive officer now directly owns 397,456 shares of the company's stock, valued at approximately $20,520,653.28. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Cytokinetics Stock Performance
Shares of CYTK stock opened at $51.48 on Tuesday. The firm has a market capitalization of $6.06 billion, a price-to-earnings ratio of -9.59 and a beta of 0.78. The company has a current ratio of 10.39, a quick ratio of 10.39 and a debt-to-equity ratio of 5.93. The business's 50-day moving average price is $54.29 and its 200-day moving average price is $55.91. Cytokinetics, Incorporated has a 12 month low of $30.68 and a 12 month high of $110.25.
How high could Bitcoin go?
From Weiss Ratings | Ad
Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin conference in Nashville … Where he told an adoring crowd that the U.S. would become … “The crypto capital of the planet and the Bitcoin superpower of the world.”
Learn More Here
Cytokinetics (NASDAQ:CYTK - Get Free Report) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing analysts' consensus estimates of ($1.06) by ($0.25). The business had revenue of $0.25 million for the quarter, compared to analysts' expectations of $7.61 million. During the same quarter last year, the firm earned ($1.34) earnings per share. Cytokinetics's revenue was down 71.3% on a year-over-year basis. Equities research analysts forecast that Cytokinetics, Incorporated will post -5.15 EPS for the current year.
Wall Street Analysts Forecast Growth
Several equities analysts have recently issued reports on the stock. Cantor Fitzgerald reissued an "overweight" rating on shares of Cytokinetics in a report on Friday, October 18th. The Goldman Sachs Group lowered shares of Cytokinetics from a "buy" rating to a "neutral" rating and lowered their price target for the company from $85.00 to $60.00 in a research note on Tuesday, August 13th. Needham & Company LLC restated a "buy" rating and set a $72.00 price objective on shares of Cytokinetics in a research note on Thursday, October 17th. HC Wainwright reissued a "buy" rating and issued a $120.00 target price on shares of Cytokinetics in a research note on Thursday, October 17th. Finally, JMP Securities reiterated a "market outperform" rating and issued a $78.00 price target on shares of Cytokinetics in a research note on Wednesday, September 4th. One analyst has rated the stock with a sell rating, four have issued a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $83.93.
Read Our Latest Stock Analysis on CYTK
Institutional Trading of Cytokinetics
Several institutional investors have recently modified their holdings of CYTK. J.Safra Asset Management Corp raised its position in Cytokinetics by 642.3% during the 2nd quarter. J.Safra Asset Management Corp now owns 527 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 456 shares during the last quarter. UMB Bank n.a. increased its stake in shares of Cytokinetics by 65.6% in the third quarter. UMB Bank n.a. now owns 601 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 238 shares during the period. Blue Trust Inc. raised its position in shares of Cytokinetics by 225.9% during the third quarter. Blue Trust Inc. now owns 981 shares of the biopharmaceutical company's stock worth $53,000 after acquiring an additional 680 shares during the last quarter. Values First Advisors Inc. acquired a new position in shares of Cytokinetics in the third quarter worth approximately $54,000. Finally, EntryPoint Capital LLC bought a new stake in Cytokinetics in the first quarter valued at approximately $74,000.
Cytokinetics Company Profile
(
Get Free Report)
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
